Literature DB >> 22759676

Alveolar bone grafting.

Gunvor Semb1.   

Abstract

In the 1970s, Boyne and Sands published reports on a new technique for alveolar bone grafting. They recommended that only cancellous bone be used and that the procedure be undertaken in the mixed dentition prior to canine eruption. Alveolar bone grafting prior to canine eruption soon became a routine part of the protocol for 90% of European and North American cleft teams. Several uncertainties remain however, such as the specifics of the surgical and orthodontic procedures, type of bone and donor site, and the best way to manage the space in the dental arch. Probably the commonest timing of the bone graft falls between 8 and 11 years, however there has been a trend in some centres to graft earlier in the hope of better outcome for the unerupted incisors. The influence on maxillary growth of earlier grafting has not been ascertained. A wide range of donor sites has been use but iliac crest remains the most popular. Many teams perform orthodontics prior to grafting to correct severe segment displacement or align incisors to improve surgical access. Following grafting, absence of the lateral incisor may be managed with orthodontic space closure, placement of an implant or bridgework. The introduction of alveolar bone grafting probably represents one of the most significant clinical innovations in cleft care. Hopefully, advances in tissue engineering will replace the need for transplantation of autogenous bone, or will provide an in-situ biological solution to the generation of a continuous bone fill across the alveolar cleft.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22759676     DOI: 10.1159/000337666

Source DB:  PubMed          Journal:  Front Oral Biol        ISSN: 0301-536X


  7 in total

1.  Locally delivered salicylic acid from a poly(anhydride-ester): impact on diabetic bone regeneration.

Authors:  Keisuke Wada; Weiling Yu; Mohamad Elazizi; Sandrine Barakat; Michelle A Ouimet; Roselin Rosario-Meléndez; Joseph P Fiorellini; Dana T Graves; Kathryn E Uhrich
Journal:  J Control Release       Date:  2013-07-01       Impact factor: 9.776

2.  Incidence of complications in secondary alveolar bone grafting of bilateral clefts with premaxillary osteotomy: a retrospective cohort study.

Authors:  Gerhard K P Bittermann; Robert J J van Es; Adrianus P de Ruiter; Michael H Frank; Arnold J N Bittermann; Aebele B Mink van der Molen; Ron Koole; Antoine J W P Rosenberg
Journal:  Clin Oral Investig       Date:  2019-06-26       Impact factor: 3.573

3.  Correlation between alveolar cleft morphology and the outcome of secondary alveolar bone grafting for unilateral cleft lip and palate.

Authors:  Xinlei Yu; Yiping Huang; Weiran Li
Journal:  BMC Oral Health       Date:  2022-06-22       Impact factor: 3.747

4.  Immobilization of murine anti-BMP-2 monoclonal antibody on various biomaterials for bone tissue engineering.

Authors:  Sahar Ansari; Marcelo O Freire; Eun-Kyoung Pang; Alaa I Abdelhamid; Mohammad Almohaimeed; Homayoun H Zadeh
Journal:  Biomed Res Int       Date:  2014-07-23       Impact factor: 3.411

Review 5.  Management of the premaxilla in the treatment of bilateral cleft of lip and palate: what can the literature tell us?

Authors:  Gerhard K P Bittermann; Ad P de Ruiter; Nard G Janssen; Arnold J N Bittermann; Aebele M van der Molen; Robert J J van Es; Antoine J W P Rosenberg; R Koole
Journal:  Clin Oral Investig       Date:  2015-09-16       Impact factor: 3.573

6.  An innovative approach in the management of alveolar clefts with bone graft harvest from maxillary tuberosity and mandibular wisdom molar odontectomy sites: A case report.

Authors:  Symon Guthua; Peter M Ng'ang'a; Krishan Sarna; Martin Kamau
Journal:  Clin Case Rep       Date:  2021-12-26

7.  Comparative Volume Analysis of Alveolar Defects by 3D Simulation.

Authors:  Pang-Yun Chou; Rafael Denadai; Rami R Hallac; Sarayuth Dumrongwongsiri; Wei-Chuan Hsieh; Betty Cj Pai; Lun-Jou Lo
Journal:  J Clin Med       Date:  2019-09-06       Impact factor: 4.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.